Compare ARDX & ORC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | ORC |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2014 | 2013 |
| Metric | ARDX | ORC |
|---|---|---|
| Price | $5.98 | $7.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 2 |
| Target Price | ★ $10.65 | N/A |
| AVG Volume (30 Days) | 2.7M | ★ 5.4M |
| Earning Date | 10-30-2025 | 10-23-2025 |
| Dividend Yield | N/A | ★ 19.59% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.57 |
| Revenue | ★ $398,234,000.00 | $80,187,000.00 |
| Revenue This Year | $22.71 | $82.99 |
| Revenue Next Year | $27.81 | $61.79 |
| P/E Ratio | ★ N/A | $12.81 |
| Revenue Growth | ★ 58.12 | 5.93 |
| 52 Week Low | $3.21 | $5.69 |
| 52 Week High | $6.78 | $9.01 |
| Indicator | ARDX | ORC |
|---|---|---|
| Relative Strength Index (RSI) | 57.69 | 56.06 |
| Support Level | $5.49 | $7.14 |
| Resistance Level | $6.02 | $7.41 |
| Average True Range (ATR) | 0.28 | 0.11 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 75.00 | 84.62 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.